Climb Bio, Inc.
NASDAQ:CLYMBiotechnology
Healthcare
$9.30 +0.17%
+$0.02 today
- Market cap
- $546.27M
- Beta
- 0.10
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.77
52W Low $1.17High $12.48
Volume 0.87M
Average 0.88M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$54.36M
FY 2025 · Annual
Investing Cash Flow
$2.83M
FY 2025 · Annual
Financing Cash Flow
-$21,000.00
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (47.48M) | (45.24M) | (35.12M) | (73.9M) | (59.85M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 97K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.74M | 6.99M | 12.81M | 5.56M | 8.05M |
| Change in Working Capital | (4.17M) | 210K | 3.76M | 1.7M | (601K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 318K | (653K) | (686K) | (1.14M) | 1.56M |
| Other Working Capital | (4.49M) | 863K | 4.45M | 2.84M | (2.17M) |
| Other Non-Cash Items | 11.84M | 674K | (2.05M) | 51.08M | (2.06M) |
| Operating Cash Flow | (36.07M) | (37.37M) | (20.6M) | (15.56M) | (54.36M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (186K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (114.97M) | (87.96M) | (58.45M) | (132.2M) | (108.08M) |
| Sales of Investments | 0 | 122.4M | 127.43M | 20.75M | 111.1M |
| Other Investing Activities | 0 | 0 | 0 | (9.65M) | 0 |
| Investing Cash Flow | (114.97M) | 34.44M | 68.98M | (121.09M) | 2.83M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 83.14M | 0 | 841K | 119.75M | (21K) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 149K | 0 | 0 | 10.98M | 0 |
| Financing Cash Flow | 177.23M | 0 | 841K | 130.73M | (21K) |
| Effect of Forex Changes | 245K | (408K) | 304K | 42K | 0 |
| Net Change in Cash | 26.44M | (3.34M) | 49.53M | (5.88M) | (51.54M) |
| Free Cash Flow | (36.07M) | (37.37M) | (20.6M) | (15.56M) | (54.54M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$59.9M
+ D&A$97.0K
+ Stock-Based Comp$8.1M
+ Deferred Tax$0
- Working Capital-$601.0K
- Other Non-Cash-$2.1M
= Operating Cash Flow-$54.4M
- Capex-$186.0K
= Free Cash Flow-$54.5M
Analysis
FY2025 free cash flow is -$54.5M. FCF conversion is 91.1% of net income. Operating cash flow was -$54.4M, with capex of -$186.0K. The largest bridge item is Stock-Based Comp at $8.1M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| S-3ASR | S-3ASR filing | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 |
Does CLYM generate free cash flow?
Climb Bio, Inc. (CLYM) generated -$54.54M of free cash flow in fiscal 2025.
How much operating cash flow does CLYM produce?
Operating cash flow was -$54.36M, before capital expenditures of $186,000.00.
Continue the stock analysis
Jump to another research area for this company.